Aristotle Atlantic Partners LLC Purchases 15,608 Shares of Eli Lilly and Company (NYSE:LLY)

Aristotle Atlantic Partners LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 61.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,177 shares of the company's stock after purchasing an additional 15,608 shares during the period. Eli Lilly and Company accounts for 1.0% of Aristotle Atlantic Partners LLC's investment portfolio, making the stock its 24th biggest position. Aristotle Atlantic Partners LLC's holdings in Eli Lilly and Company were worth $31,789,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LLY. Norges Bank bought a new position in Eli Lilly and Company in the 4th quarter worth about $8,407,908,000. Proficio Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 100,387.1% during the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after purchasing an additional 5,197,038 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the last quarter. Capital International Investors raised its stake in Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $1,240,653,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. UBS Group dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,002.80.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $825.10 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm has a market cap of $782.34 billion, a P/E ratio of 70.46, a P/E/G ratio of 1.40 and a beta of 0.51. The business's 50 day moving average price is $825.36 and its 200-day moving average price is $816.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.58 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.